Definitive Healthcare acquires Monocl, adding expert data to life sciences stack
The deal pulls a global expert-profiling platform into Definitive's commercial intelligence suite for drug developers.
Definitive Healthcare has acquired Monocl, a platform that builds professional profiles on millions of medical and scientific experts worldwide, according to the company's press release. Terms were not disclosed.
The acquisition slots Monocl's expert data into Definitive's life sciences offering, aimed at pharma and biotech clients running clinical development and commercialization workflows. The pitch: a single place to find and engage the right key opinion leaders (KOLs) for a given disease area, alongside the provider, payer, and patient data Definitive already sells.
What Monocl does
Monocl's product is a searchable database of expert profiles built from publications, clinical trial participation, conference activity, guideline authorship, and other public footprints. Pharma medical affairs teams, clinical operations groups, and commercial launch teams use this kind of data to identify investigators for trials, advisors for advisory boards, and speakers for peer-to-peer programs.
Definitive frames the historical pain point as time, completeness, and inefficiency. Manual KOL identification, the company says in the release, has been slow and incomplete; Monocl's platform offers real-time search across a global expert pool.
Where this fits in the commercial intelligence stack
Definitive Healthcare's core business is selling provider, payer, and claims-derived data to life sciences and healthcare technology customers. Adding an expert-data layer is a logical extension: the same pharma client buying Definitive's HCP and account data for sales targeting also needs expert-identification data for medical affairs and clinical trial site selection. Bundling the two reduces the number of vendors a life sciences commercial team has to manage.
This is a different segment from the financial-services expert networks (GLG, Guidepoint, Third Bridge, AlphaSense/Tegus) that institutional investors use for primary research. The Monocl-style "healthcare KOL identification" market sits inside life sciences itself, sold to medical affairs and commercial teams rather than buy-side analysts. Workflows overlap (find an expert, engage them, document the interaction) but compliance regimes differ: Sunshine Act reporting, fair-market-value rate cards, and aggregate-spend tracking dominate the pharma side.
Why it matters
What's next: integration speed. Acquisitions of data products inside larger platforms tend to live or die on whether the source data stays fresh after the transition and whether the workflow the acquirer wraps around it matches what the original product's users were doing. Watch the next two earnings cycles for retention commentary on the Monocl book of business.
Powering institutional-grade transcription for expert networks.
INFLXD provides AI-powered, human-edited transcription with sub-1% error rates for the world's leading expert networks and financial research firms.
Visit inflxd.com →Keep reading.
Magnetar prepares AI-agent equity fund for 2026 launch
The $18 billion firm is building a long-biased equity strategy where hundreds of AI agents handle research work normally done by analyst teams.
Accenture Ventures takes stake in AlphaSense, sets agentic workflow partnership
The consulting firm's venture arm backs the market intelligence platform as the two move to embed AlphaSense data inside enterprise AI agents.
AlphaSense raises $350M at $7.5B valuation, crosses $600M ARR
The market intelligence platform extends its content moat and AI roadmap with fresh capital from J.P. Morgan Private Capital and Viking Global Investors.